Immunotherapy in Nonsmall Cell Lung Cancer (Basket of Choices)

Abhishek Raj

doi:10.4103/ijmpo.ijmpo_101_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 587-590
DOI: 10.4103/ijmpo.ijmpo_101_20

Courting Controversy

Immunotherapy in Nonsmall Cell Lung Cancer (Basket of Choices)

Abhishek Raj

Department of Medical Oncology, Fortis Memorial Research Institute, Gurugram, Haryana, India

› Author Affiliations

Abstract

The advent of immunotherapy has changed the landscape of lung cancer management over the past few years. Once a uniformly fatal disease with limited therapeutic options, the physicians now have a myriad of options to choose from while offering therapy to a patient of metastatic nonsmall cell lung cancer.

Keywords

Atezolizumab - checkpoint inhibitors - chemotherapy - nonsmall cell lung cancer - PDL1 testing - pembrolizumab

Full Text

References

References
1 Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-50
2 Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP. et al Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28
3 Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33
4 Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A. et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37: 537
5 Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92
6 Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M. et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2020; 38: 1505-17
7 Zhou Y, Lin Z, Zhang X, Chen C, Zhao H, Hong S. et al. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: Pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer 2019; 7: 120
8 West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924-37
9 Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-301
10 Reck M, Mok TS, Nishio M, Jotte RM, Cappuzzo F, Orlandi F. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019; 7: 387-401
11 Papadimitrakopoulou VA, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G. et al. Impower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. 2018 World Conference on Lung Cancer. Abstract OA05.07. Presented September 24, 2018.